Node Negative Early Stage Breast Cancer Patients Benefit From Taxotere(R)-Based Chemotherapy

Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced that for women with high-risk node-negative early stage breast cancer adjuvant treatment (post surgery) with Taxotere(R) (docetaxel) Injection Concentrate as part of the TAC regimen (Taxotere(R), dox

More: continued here

Filed under: Breast Cancer on June 1st, 2008